Bajaj Healthcare share hits all-time high after firm launches black fungus drug
BajajHealthcare share rose to a record high of Rs 700 rising 10% against previousclose of Rs 636.05 on BSE
BusinessToday.In | May 28, 2021 | Updated 16:40 IST
The company has received nod from FDA (Food and Drugs Administration) Gandhi Nagar, Gujarat (India), to manufacture and market Posaconazole API as approved medication for treating Mucormycosis in India Bajaj Healthcare said it will commence its commercial production from the first week of June 2021.
Share of Bajaj Healthcare share hit all time high today after the company launched drug to treat black fungus infection in COVID-19 patients. Bajaj Healthcare share rose to a record high of Rs 700 rising 10% against previous close of Rs 636.05 on BSE.